- Home
- ROIV vs LNTH Comparison
ROIV vs LNTH Comparison
Compare ROIV & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- LNTH
- Stock Information
- Founded
- ROIV 2014
- LNTH 1956
- Country
- ROIV United Kingdom
- LNTH United States
- Employees
- ROIV N/A
- LNTH N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ROIV Health Care
- LNTH Health Care
- Exchange
- ROIV Nasdaq
- LNTH Nasdaq
- Market Cap
- ROIV 8.4B
- LNTH 7.5B
- IPO Year
- ROIV N/A
- LNTH 2015
- Fundamental
- Price
- ROIV $10.91
- LNTH $75.13
- Analyst Decision
- ROIV Buy
- LNTH Strong Buy
- Analyst Count
- ROIV 4
- LNTH 5
- Target Price
- ROIV $17.50
- LNTH $133.80
- AVG Volume (30 Days)
- ROIV 5.5M
- LNTH 1.5M
- Earning Date
- ROIV 05-29-2025
- LNTH 05-07-2025
- Dividend Yield
- ROIV N/A
- LNTH N/A
- EPS Growth
- ROIV N/A
- LNTH N/A
- EPS
- ROIV N/A
- LNTH 3.53
- Revenue
- ROIV $122,585,000.00
- LNTH $1,536,699,000.00
- Revenue This Year
- ROIV N/A
- LNTH $4.96
- Revenue Next Year
- ROIV N/A
- LNTH $10.25
- P/E Ratio
- ROIV N/A
- LNTH $21.28
- Revenue Growth
- ROIV 140.04
- LNTH 12.53
- 52 Week Low
- ROIV $8.73
- LNTH $75.00
- 52 Week High
- ROIV $13.06
- LNTH $126.89
- Technical
- Relative Strength Index (RSI)
- ROIV 52.03
- LNTH 27.24
- Support Level
- ROIV $10.58
- LNTH $77.01
- Resistance Level
- ROIV $11.77
- LNTH $81.50
- Average True Range (ATR)
- ROIV 0.33
- LNTH 3.52
- MACD
- ROIV -0.04
- LNTH -1.61
- Stochastic Oscillator
- ROIV 28.57
- LNTH 0.35
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.